HIMS falls after FDA GLP-1 drug warning overshadows Australia expansion
Hims & Hers Health shares began September in the red as an FDA warning about unapproved GLP-1 weight-loss drugs drew focus. The stock fell 4% to close at $28.44 on Tuesday.
Shares of Hims & Hers Health (HIMS) began September in the red as a Food and Drug Administration (FDA) warning about unapproved GLP-1 weight-loss drugs overshadowed the telehealth company’s expansion into Australia.HIMS stock fell 4% on Tuesday to end the session at $28.44.FDA Warns On Compounded G…